An observational study in Alzheimer Disease, Mild Cognitive Impairment and Dementia, sponsored by C2N Diagnostics. Completed at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by C2N Diagnostics · Observational
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.
By gathering feedback from healthcare providers on patient selection, intended use, and anticipated outcomes and continued or revised care plans as a result of the test report, C2N can better understand the impact of the test results on diagnosis and patient management.
3,766 studies on the registry are indexed under Alzheimer Disease; 881 are open to participants now.
This study's enrollment of 366 is above the median of 200 across 780 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →C2N Diagnostics is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Memory Specialists actively practicing in the United States were asked to complete the QI 1.0 survey with expertise in caring for patients with mild cognitive impairment and knowledge of Alzheimer's Disease in terms of expertise and volume of patients served. This may include nurse practitioners or physician assistants who work in the field of Memory Disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinician Survey post receipt of PrecivityAD blood test result
Also known as: AD
evaluate patient selection for the blood test through analysis of clinician survey responses.
retrospective analysis of clinician survey data collected during a single timepoint
Time frame: 2021 - 2023
evaluate score interpretation for the Amyloid Probability Score (APS) through analysis of clinician survey responses.
retrospective analysis of clinician survey data collected during a single timepoint
Time frame: 2021 - 2023
Plan to share: No
Ran from Mar 2021 to primary completion in Oct 2022, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
C2N Diagnostics